Lipocine Inc. (LPCN)
| Market Cap | 13.11M -7.0% |
| Revenue (ttm) | 3.74M -13.4% |
| Net Income | -9.33M |
| EPS | -1.29 |
| Shares Out | 8.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 206,495 |
| Open | 1.620 |
| Previous Close | 1.590 |
| Day's Range | 1.560 - 1.640 |
| 52-Week Range | 1.360 - 12.370 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 5.00 (+214.47%) |
| Earnings Date | Nov 5, 2026 |
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LPCN stock is "Buy." The 12-month stock price target is $5.0, which is an increase of 214.47% from the latest price.
News
Lipocine doses first patient in Phase 3 study evaluating LPCN 1154
Lipocine (LPCN) announced that the first participant has been dosed in BLOOM, the company’s Phase 3 study evaluating LPCN 1154 for postpartum depression. LPCN 1154 is being developed as a…
Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use in postpartum depression Approximately 120 participants planned for the study, which incorporates insights from the pr...
Lipocine Announces Financial Results for the Third Quarter of 2026
SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results f...
Lipocine Quarterly report: Q3 2026
Lipocine has published its Q3 2026 quarterly earnings report on November 5, 2026.
Lipocine Earnings release: Q3 2026
Lipocine released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Lipocine Slides: Corporate presentation
Lipocine has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2026.
3 Penny Stocks to Watch Today, October 8
China SXT Pharmaceuticals ($SXTC), Baiya International Group ($BIYA), and Lipocine Inc. ($LPCN) are among the penny stocks to watch on October 8, according to TipRanks’ Penny Stock Screener Tool. A pe...
Lipocine announces Health Canada approved TLANDO capsules
Lipocine (LPCN) announced that, through Lipocine’s licensing partner Verity Pharmaceuticals, Health Canada has approved TLANDO capsules for testosterone replacement therapy in adult males for the cond...
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipoc...
H.C. Wainwright sets $4 price target on Lipocine
H.C. Wainwright reiterates a Neutral rating on Lipocine (LPCN) after the company announced last week the initiation of the Phase 3 BLOOM trial of LPCN1154 for the treatment of severe…
Lipocine Slides: Conference Presentation
Lipocine has posted slides in relation to its latest quarterly earnings report, which was published on September 16, 2026.
Lipocine initiates Phase 3 study of LPCN 1154 for postpartum depression
Lipocine (LPCN) announced the initiation of BLOOM, a Phase 3 study evaluating LPCN 1154 for PPD. First participant dosing is expected in early Q4 2026. LPCN 1154 is being developed…
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned; fi...
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company mana...
Lipocine reports Q2 EPS (32c) vs. (41c) last year
Reports Q2 revenue $2.4M vs. $123K last year. As of June 30, 2026, Lipocine (LPCN) had $23.3 million of unrestricted cash, cash equivalents, and marketable investment securities, compared to $14.9…
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results f...
Lipocine Quarterly report: Q2 2026
Lipocine has published its Q2 2026 quarterly earnings report on August 4, 2026.
Lipocine Earnings release: Q2 2026
Lipocine released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Lipocine Appoints Michael J. Grissinger to Board of Directors
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral del...
Lipocine Transcript: KOL event
LPCN 1154, an oral brexanolone for postpartum depression, showed rapid, durable, and clinically meaningful symptom improvement in subgroup analyses after excluding data from an outlier site. The drug demonstrated a favorable safety profile, rapid onset, and potential advantages over current treatments, supporting a streamlined regulatory path and broader market potential.
Lipocine Slides: KOL event
Lipocine has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time SALT LAKE CITY, June 4, 2026 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company focused on th...
Lipocine Transcript: A.G.P.'s Annual Virtual Healthcare Conference
Phase III results for a postpartum depression treatment showed rapid, significant efficacy in key subgroups when excluding an anomalous site, with a strong safety profile and clear differentiation from current therapies. Sufficient funding is in place for a new trial, with interim results expected by late Q1 next year.
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral del...
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and infla...